hotspot -WSS

hotspot

author：explore 2025-10-01 07:40:29 - browse：2443

This image provided by Amylyx Pharmaceuticals shows the drug Relyvrio. The maker of a much-debated drug for Lou Gehrig’s disease said Friday, March 8, 2024 its therapy failed to help patients in a large follow-up study, but stopped short of committing to follow through on a prior pledge to pull the drug from the U.S. market. — Relyvrio, an ALS drug made by Amylyx Pharmaceuticals, failed to beat placebo in a key clinical trial. Amylyx Pharmaceuticals via AP

The latest disappointment in amyotrophic lateral sclerosis research brought crushing news for patients and physicians, forcing the community to consider just what to do with an approved medicine that doesn’t appear to work.

Amylyx Pharmaceuticals’ announcement Friday that its drug, marketed as Relyvrio, failed to beat placebo in a pivotal study marks “a sad day for us, but we have to believe the data,” said Mary Catherine Collet, an ALS advocate. “These are hard scientific facts that we have to face, and I appreciate that they’re not trying to spin us like some cheerleading practice.”

The question now is whether Relyvrio, approved in 2022, should be removed from the market entirely — and whether the Food and Drug Administration made a mistake by authorizing it in the first place. After years of pressure from patient advocates, the agency has taken a more flexible approach to medicines for devastating, incurable diseases like ALS. But the case of Relyvrio, which made $381 million in sales and $49 million in profit for Amylyx last year, has underlined questions about the limits of regulatory leniency.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

focus

WSS

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

New brain studies show LSD's effects on the brain in full color

Think you might have Covid

Copay coupons to count toward deductibles, after Biden court move

Hospitals consider fixing cancer drug shortages on their own

How housing is health care on Long Island

entertainment

hotspot

explore

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Popular nasal decongestant doesn't actually relieve congestion

Medical records are filled with copy

New Covid vaccine is recommended for everyone 6 months or older

Supreme Court strikes down use of affirmative action

Why doctors need education on FDA device approval process

State Dept. review finds Biden bears some blame for Afghanistan failures

The tragedy of Johnson & Johnson’s Covid vaccine

Medicare proposal to cover medical devices draws a mixed reaction

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Wikipedia

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Medicare Advantage today, explained in one chart

Popular nasal decongestant doesn't actually relieve congestion

The surgeon had a dilemma only a Nazi medical text could resolve

Independent physicians launch a new lobbying group

EU regulator recommends expanding Mounjaro approval to obesity

hotspot

focus

explore

Wikipedia